The Year in Biotech So Far and What’s Ahead

The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP Vantage, about the trends in the first half of the year, whether 2014 will set new records for M&A activity, and the threats out there that may put an end to the good times.